Video

Treat-to-Target in Rheumatoid Arthritis

Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.

Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.

Related Videos
Related Content
Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com
December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors
December 19th 2024

ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Biosimilars, Digital Tool, Patients, Health Care Professionals, Education | Image Credit: © Pixels Hunter | stock.adobe.com
December 17th 2024

Investigators Develop Training Tool to Improve Prescriber-Patient Communication About Biosimilars

Ashley Gallagher, Associate Editor
senior or elderly old lady woman patient on wheelchair looking out the window so sad at home
December 16th 2024

FDA Grants Breakthrough Therapy Designation to Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis

Luke Halpern, Assistant Editor